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The aspartate/glutamate carrier isoform 1 is an essential mitochondrial transporter that exchanges
intramitochondrial aspartate and cytosolic glutamate across the inner mitochondrial membrane. It is
expressed inbrain, heart andmuscle and is involved in important biological processes, includingmyelina-
tion. However, the signals that regulate the expression of this transporter are still largely unknown. In this
studywe ﬁrst identify a CREB binding sitewithin the aspartate/glutamate carrier gene promoter that acts
as a strong enhancer element in neuronal SH-SY5Y cells. This element is regulated by active, phosphory-
lated CREB protein and by signal pathways thatmodify the activity of CREB itself and,most noticeably, by
intracellular Ca2+ levels. Speciﬁcally, aspartate/glutamate carrier gene expression is induced via CREB by
forskolinwhile it is inhibited by the PKA inhibitor, H89. Furthermore, the CREB-induced activation of gene
expression is increased by thapsigargin,which enhances cytosolic Ca2+,while it is inhibited by BAPTA-AM
that reduces cytosolic Ca2+ or by STO-609,which inhibits CaMK-IVphosphorylation.We further show that
CREB-dependent regulation of aspartate/glutamate carrier gene expression occurs in neuronal cells in
response to pathological (inﬂammation) and physiological (differentiation) conditions. Since this carrier
is necessary for neuronal functions and is involved in myelinogenesis, our results highlight that targeting
of CREB activity and Ca2+ might be therapeutically exploited to increase aspartate/glutamate carrier gene
expression in neurodegenerative diseases.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND. IntroductionThe mitochondrial aspartate/glutamate carrier isoform 1
AGC1), encoded by the SLC25A12 gene, is a member of the
olute carrier family 25 (Palmieri, 2004, 2013). This transporter
Abbreviations: A, -amyloid; AGC1, aspartate/glutamate carrier isoform 1;
PP, amyloid precursor protein; BAPTA-AM, 1,2-bis(2-aminophenoxy) ethane-
,N,N′ ,N′-tetraacetic acid tetrakis(acetoxymethyl ester); ChIP, chromatin immuno-
recipitation; P-CREB, phospho-cAMP-response-element-binding protein; T-CREB,
otal-cAMP-response-element-binding protein db-cAMP, dibutyryl-cAMP; EMSA,
lectrophoreticmobility-shift assay; IBMX, isobutylmethylxanthine; IFN, inter-
eron gamma; LUC, luciferase; NAA, N-acetylaspartate; NRG-1, neuregulin-1; PKA,
AMP-dependent protein kinase; SAP97, synapse-associated protein-97; siCREB,
iRNA targeting CREB; siRNA, small interfering RNA; SYP, synaptophysin; TNF,
umor necrosis factor alpha; WB, Western-blotting.
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catalyzes an exchange between intramitochondrial aspartate and
cytosolic glutamate plus a proton across the mitochondrial mem-
brane (Palmieri et al., 2001). It plays an important role in the
malate/aspartate shuttle, in urea synthesis and in gluconeogene-
sis from lactate. As a component of the malate/aspartate shuttle,
AGC1 transfers the reducing equivalents of NADH+H+ from the
cytosol into mitochondria (Indiveri et al., 1987; Palmieri, 2004).
Two AGC isoforms, AGC1 and AGC2, are present in man; AGC1
is expressed in heart, skeletal muscle and brain, while AGC2 is
expressed in many tissues, particularly in the liver (Iijima et al.,
2001). AGC1 is the main AGC isoform in brain, in particular in
neurons (del Arco et al., 2002; Contreras et al., 2010). The N-
terminal domain of its 678-amino acid sequence contains four
EF-hand Ca2+-binding sites, which were conclusively shown to
bind Ca2+ in vitro and in vivo (del Arco and Satrustegui, 1998;
Lasorsa et al., 2003). Through this interaction, cytosolic Ca2+ stimu-
lates AGC1 and mitochondrial metabolism activity (Palmieri et al.,
2001; Lasorsa et al., 2003; Contreras et al., 2007). Instead, the C-
terminaldomainofAGC1contains six transmembranedomainsand
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Germany) (Echave et al., 2009), 100nM thapsigargin (Sigma)
(Pulver et al., 2004) or 10M 1,2-bis(2-aminophenoxy) ethane-
N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-
AM) (Sigma) (Petroni et al., 2013) 16h after having been depleted58 A. Menga et al. / The International Journal o
characteristicmitochondrial carrier family (MCF) signaturemotif,
ike all the other members of the SLC25 or MC family (Palmieri,
004).
Studies in animal models have highlighted the relevance of
GC1 in the physiology of neurons. AGC1 knockout mice showed a
ramatic drop in brain aspartate levels, with a concomitant reduc-
ion in N-acetylaspartate (NAA) synthesis and hypomyelination
Jalil et al., 2005). The connection between lack of AGC1 and drop in
AA synthesis may due to the lack of mitochondrial aspartate out-
ut, which in turn would limit availability of NAA-derived acetate
eeded for lipidbiosynthesis resulting inhypomyelination.Numer-
us studies have indeeddemonstrated that acetatemoieties ofNAA
re incorporated into brain lipids during the development of the
entral nervous system, hence strongly suggesting that AGC1 may
e crucially involved in the myelination process (D’Adamo and
atsu, 1966; D’Adamo et al., 1968; Patel and Clark, 1979; Burri
t al., 1991;Mehta andNamboodiri, 1995; Chakraborty et al., 2001;
edeen et al., 2006; Namboodiri et al., 2006; Moffett et al., 2013).
n support of this conclusion, children harboring mutations of the
LC25A12genedisplay severedevelopmental delay, epilepsy, hypo-
onia hallmarked by hypomyelination and decreased NAA in the
rain (Wibom et al., 2009; Falk et al., 2014). The chromosomal
egion containing the gene encoding AGC1 has also been identi-
ed as a putative autism susceptibility locus (Ramoz et al., 2004;
urunen et al., 2008; Palmieri et al., 2010). In addition, interest in
he involvement of mitochondria in neurodegenerative and neu-
oinﬂammamtory disorders, such as Parkinson’s and Alzheimer’s
isease, and multiple sclerosis is emerging (Lin and Beal, 2006)
Despite the well-established role of NAA in myelin biosyn-
hesis, it is still unknown in which subcellular compartment the
iosynthesis occurs. Different studies have provided evidence that
he aspartate-N-acetyltransferase (Asp-NAT), the enzyme that cat-
lyzes the biosynthesis of NAA, is localized in the mitochondria
Patel and Clark, 1979; Madhavarao et al., 2003; Arun et al., 2009).
owever, other studies performed in primary neuronal cultures
stablished that Asp-NAT is located in the endoplasmic reticulum
swell (Wiame et al., 2009; Tahay et al., 2012). A colocalizationwas
eported by other authors (Lu et al., 2004; Ariyannur et al., 2010).
The cAMP response element-binding protein (CREB) has been
idely investigatedas akeymetabolic sensor and regulator of ener-
etic homeostasis (Iacobazzi et al., 2005; Altarejos and Montminy,
011). Importantly, CREB protein is also one of the major trans-
riptional factors that regulates the expression of genes necessary
or the development and function of the nervous system and such
ctivities require CREB binding to – and transcription regulation
f genes containing the cAMP response elements (CRE) (Lonze and
inty, 2002).
The transcriptional activity of CREB is induced through serine
hosphorylation in its conserved kinase inducible domain by the
AMP-dependent protein kinase (PKA) (Sands and Palmer, 2008),
a2+/calmodulin protein kinase (Enslen et al., 1994), ribosomal S6
inase (RSK) and mitogen/stress-activated kinase (MSK) families
Deak et al., 1998). Furthermore, the phosphorylation-dependent
ctivation of CREB involves its interaction with basal transcrip-
ion factors, adaptor(s), constitutive and inducible coactivators,
hich contribute to form a transcriptional complex (Sheng and
reenberg, 1990). Although the transport activity and the func-
ional role of some mutations of AGC1 have been investigated,
othing is known about the molecular mechanisms of its gene
xpression in any cell (Palmieri et al., 2001; Lasorsa et al., 2003;
amoz et al., 2004; Jalil et al., 2005; Contreras et al., 2007; Wibom
t al., 2009).In this work we demonstrate that in neuronal cells CREB is
main activating transcription factor of AGC1 gene expression
nd cytosolic Ca2+ stimulates AGC1 gene expression through CREB.
urthermore, we also shown that AGC1 is down-regulated inemistry & Cell Biology 60 (2015) 157–166
neuroinﬂammation and is up-regulated inneuronal differentiation.
Therefore our data provide an important link for the activation of
AGC1 in physiological and pathological conditions.
2. Experimental
2.1. Construction of plasmids
To analyze thepromoter of thehumanAGC1gene, reporter plas-
mid constructs were prepared. Progressive deletion fragments of
the region from −1995 to −15bp of the AGC1 gene promoter were
ampliﬁed by PCR and cloned into the pGL3 basic-luciferase (LUC)
vector (Promega) upstream of the LUC gene-coding sequence as
previously described (Iacobazzi et al., 2009a). The CREB expression
vector (pcDNA3-CREB) was obtained by cloning the human CREB
(GenBank Accession No. NM 004379.3) cDNA into the pcDNA3.1
vector (Invitrogen). The sequences of all constructs were veriﬁed
by DNA sequencing.
2.2. Cell culture, RNA interference and transient transfection
Human neuroblastoma SH-SY5Y cells (ATCCID: CRL-2266)were
grown as described (Infantino et al., 2013a). Transient transfec-
tion experiments were performed using FuGENE® HD Transfection
Reagent (Promega) and 0.5g of each construct reported above,
as previously described (Iacobazzi et al., 2009b). LUC activity in cell
extractswasmeasured in a96-well plate format byusing aVICTOR3
multi-label plate reader (PerkinElmer, Waltham, MA, USA). The
extent of transfection was normalized by -galactosidase activity
(Infantino et al., 2011). In RNA interference experiments, the spe-
ciﬁc pre-designed small interfering RNA (siRNA) targeting human
CREB (s3489, Ambion) was transfected in SH-SY5Y cells (Iacobazzi
et al., 2009c).
2.3. SH-SY5Y differentiation
For SH-SY5Y cell differentiation, growth medium was replaced
with serum-free medium for 16h. The cells were then stimulated
with the differentiation medium consisting of serum-free medium
supplemented with 0.5mM 3-isobutyl-1-methylxanthine (IBMX;
Sigma–Aldrich, St. Louis, MO, USA) and 1mM dibutyryl-cAMP (db-
cAMP; Sigma) (Deng et al., 2001). SH-SY5Y cell differentiation was
monitored by evaluating cell morphology under phase-contrast
microscopy and by measuring the expression levels of neuron-
speciﬁc synaptophysin (SYP) and synapse-associated protein-97
(SAP97), two neuronal differentiation markers. Cells were har-
vested at the indicated timepoints and total RNAandproteinswere
isolated and analyzed.
2.4. Treatments
Where indicated, SH-SY5Y cells were incubated with 10M
forskolin (Sigma) (Monaghan et al., 2008), 20ng/ml recombinant
human neuregulin-1 (NRG-1, Immuno-Tools GmbH, Friesoythe,of serum; 10M H89 (Sigma) (Monaghan et al., 2008) or 10g/ml
STO-609 (Sigma) (Tokumitsu et al., 2002) were added 1h prior.
Cells were harvested and total RNA and proteins were isolated and
analyzed.
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.5. Activating stimuli
SH-SY5Y cells were treated up to 96h with a combination
f 500U/ml IFN (Immuno-Tools GmbH, Friesoythe, Germany),
000U/ml TNF (Sigma–Aldrich) and 10ng/ml IL-1 (Immuno-
ools GmbH, Friesoythe, Germany). Cells were harvested at the
ndicated time points and total RNA and proteinswere isolated and
nalyzed.
.6. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were per-
ormed as previously reported (Iacobazzi et al., 2008). Brieﬂy,
×107 SH-SY5Y cells (exposed up to 72h to 0.5mM IBMX
nd 1mM db-cAMP) were ﬁxed by 1% formaldehyde at 37 ◦C
or 10min; afterwards, the cells were lysed and fragments of
00–500bp. The chromatin was immunoprecipitated for 14–16h
t 4 ◦C using a speciﬁc antibody to CREB (Thermo Fisher Sci-
ntiﬁc, Catalog No. MA5-15154). After reverse cross-linking,
hromatin immunoprecipitates were puriﬁed, then 2l of each
ample was analyzed by PCR (35 cycles) using a forward primer
5′-CGTCCCATGCCAATTTAGGAGCAT-3′) and a reverse primer
5′-AGGTTCCGACGGATCAAAGAGCAC-3′) suitable to amplify the
565/−409bp region of the AGC1 gene promoter.
.7. Other methods
Electrophoretic mobility shift assays (EMSA) were performed
ccording to Menga et al. (Menga et al., 2013). Brieﬂy, a biotin 3′-
nd labeled DNA probe from the −531 to −511bp region of the
uman AGC1 gene promoter was incubated with 10g of SH-SY5Y
uclear extracts (exposed up to 24h to 0.5mM IBMX and 1mM db-
AMP) for 20min at room temperature. Total RNA was extracted
rom 3×106 SH-SY5Y cells, and reverse transcription was per-
ormed as described previously (Infantino et al., 2007). Real-time
CR was conducted as described (Convertini et al., 2011). Assay-
n-demand for humanAGC1(Hs00186535 m1) and human-actin
4326315E) was purchased from Applied Biosystems. Western
lotting analysis was performed according to Infantino et al.
2013b). Anti-AGC1 (sc-271056, Santa Cruz Biotechnology), anti-
-actin (Santa Cruz Biotechnology), anti-T-CREB, anti-P-CREB (Ser
33) (sc-101663, Santa Cruz Biotechnology), anti-SAP97 (sc-9961,
anta Cruz Biotechnology), anti-SYP (sc-9116, Santa Cruz Biotech-
ology) or anti--amyloid (sc-9129, Santa Cruz Biotechnology)
ntibodies were used for immunoreaction. Band intensities were
nalyzed densitometrically using a Fluor-S MultiImager and Quan-
ity One software (Bio-Rad). Cell viability was evaluated by the
ellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega).
n brief, cells were seeded onto 96-well microtiter plates and
reated with siRNA targeting CREB (siCREB) for up to 72h. After
ncubation, 15l of the Dye Solution was added to each well and
he cells were incubated for 4h at 37 ◦C. Subsequently, solubili-
ation solution/stop mix (100l) was added to each well and the
ells were incubated for 1h at 37 ◦C to promote the solubilization
f formazan crystals. The level of MTT formazan was determined
ymeasuring its absorbance at 570nmusing a 96-well plate reader
VICTOR3, PerkinElmer)..8. Statistical analysis
All data are presented as means± S.D. for the number of exper-
ments indicated in each case. Statistical analysis was performed
sing one-way ANOVA. p-Value <0.05 was considered statistically
igniﬁcant.emistry & Cell Biology 60 (2015) 157–166 159
3. Results
3.1. AGC1 expression is downregulated by inﬂammatory
cytokines
A typical feature of neuroinﬂammation is the presence in neu-
ronal cells of pro-inﬂammatory cytokines, such as TNF, IFN and
IL-1 (McGeer and McGeer, 1995; Akiyama et al., 2000; Heneka
et al., 2010; Zhao et al., 2011). Therefore, we asked whether the
expression of the AGC1 gene is inﬂuenced by TNF, IFN and IL-1
(individually or in combination). First, wemeasured the expression
of the A peptide, a typical marker of neurodegeneration (Blasko
et al., 1999; Zhao et al., 2011) after 24 and 96h of treatment with
TNF 1000U/ml, IFN 500U/ml and IL-1 10ng/ml alone or in
combination. No signiﬁcant effect was observed after 24h of treat-
ment (data not shown). After 96h, the A peptide was evident in
TNF and IFN individual treatments and more signiﬁcantly in the
cytokines combination treatment (Fig. 1A). SH-SY5Ycellswere sub-
sequently treatedwith the cytokines individually or in combination
for 24 or 96h. Real-time PCR performed on mRNA extracted from
TNF-, IFN- and IL-1 treated and untreated cells did not show
any change in AGC1 mRNA after 24h; whereas a decrease of about
20% was observed in cells treated with combination of TNF/IFN
and TNF/IFN/IL-1 as compared with untreated cells (Fig. 1B). A
major reduction of AGC1 gene expressionwas found in cells treated
with individual TNF (about 30%) and IFN (about 40%) after 96h.
A more signiﬁcant reduction (about 80%) was seen in the cytokines
combination treatment as compared with untreated cells (Fig. 1C).
Accordingly,Westernblot analysisdemonstratedamajor reduction
of AGC1 protein level after 96h of TNF/IFN and TNF/IFN/IL-1
treatment as compared with 24-h cytokines-treated cells (Figs. 1D
and E).
These data show that AGC1 protein levels are signiﬁcantly
down-regulated following prolonged exposure to stimuli that
mimic neuroinﬂammation.
3.2. CREB is a main regulator of AGC1 gene expression in
neuronal cells
To investigate the regulation of AGC1 gene expression in
neuronal cells, different deletion fragments of the AGC1 gene
promoter were ampliﬁed, cloned into the pGL3 basic-LUC vector
and transiently transfected into SH-SY5Y cells. The resulting
pattern of reporter LUC activity is shown in Fig. 2. Deletion of the
5′-ﬂanking region from position −1722bp to position −1398bp
(pGL3-C3-LUC vector) caused a decrease in gene reporter activity
of about 50% as compared to the activities of the constructs
pGL3-C1-LUC from −1995bp and pGL3-C2-LUC from −1722bp.
In contrast, deletion from −1081bp to −565bp (pGL3-C5-LUC
construct) resulted in a drastic increase (>200%) in reporter gene
activity, suggesting that a strong enhancer is located within
this region. Basal LUC activity was restored with deletion from
−565bp to −433bp (pGL3-C6-LUC vector). Preliminary, the
transcription start site was found at position −82bp upstream
the ATG codon. (http://dbtss.hgc.jp/index.html). To identify the
transcription factors present in construct pGL3-C5-LUC that
strongly activate AGC1 gene expression, an in silico analysis was
performed using different programs: the TFSEARCH Program
(http://www.cbrc.jp/research/db/TFSEARCH.html), the Alibaba 2.1
(http://www.gene-regulation.com/pub/programs/alibaba2/index.
html), and the LASAGNA-Search (http://biogrid-head.engr.uconn.
edu/lasagna search/). Among several potential factor-binding
motifs, a CREB binding site was present at position −525/−517bp
upstream the ATG translation codon. Because CREB is a key factor
that regulates many neural functions (Lonze and Ginty, 2002), we
investigated CREB transcriptional activity on the AGC1 gene by
160 A. Menga et al. / The International Journal of Biochemistry & Cell Biology 60 (2015) 157–166
Fig. 1. Effect of pro-inﬂammatory cytokines on AGC1 gene expression. (A) SH-SY5Y cells were treated with IFN (500U/ml), TNF (1000U/ml) and IL-1 (10ng/ml) alone
or in combination for 24 and 96h. Cells lysates were subjected to immunoblots with mature and immature APP, amyloid beta protein (A) and -actin antibodies. (B) AGC1
mRNA in SH-SY5Y cells treated for 24h with the same cytokines as in (A) was quantiﬁed by real-time PCR. Data are expressed as means± S.D. of ﬁve duplicate independent
experiments. *P<0.05 versus control, (one-way ANOVA). (C) AGC1 mRNA of SH-SY5Y cells treated for 96h as above was quantiﬁed by real-time PCR. Data are expressed
as means± S.D. of ﬁve duplicate independent experiments. *P<0.05, ***P<0.001 versus control. (D) AGC1 and -actin proteins of SH-SY5Y cells treated or untreated with
cytokines for 24h as above, were immunodetected with speciﬁc antibodies. Similar results were obtained in three independent experiments. (E) AGC1 and -actin proteins
of SH-SY5Y cells treated or untreated with cytokines for 96h as above, were immunodetected with speciﬁc antibodies. Similar results were obtained in three independent
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verexpressing CREB in SH-SY5Y cells. SH-SY5Y cells transfected
ith the pcDNA3-CREB and pGL3 basic-LUC vectors harboring the
5 fragment of the AGC1 gene promoter were incubated in the
resence or absence of forskolin, an activator of adenylate cyclase
Monaghan et al., 2008). LUC activitywas enhanced by about 35% in
ells transfected with the pcDNA3-CREB and pGL3-C5-LUC vectors
s compared to cells transfected with the pGL3-C5-LUC vector
lone used as control (Fig. 3A). Forskolin added to SH-SY5Y cells
ransfected with the pGL3-C5-LUC vector alone increased reporter
ctivity by about 100% and to cells transfected with both the pGL3-
5-LUC and pcDNA3-CREB vectors by about 200%, as compared
o control (Fig. 3A). Furthermore, forskolin-mediated increase of
he reporter activity was strongly reduced by H89, a PKA inhibitor
Monaghan et al., 2008) (Fig. 3A). In contrast, LUC activity was not
ffected by expression of CREB or by forskolin when the control
onstruct pGL3-C6-LUC (without the CREB binding site of the
GC1 gene promoter) was used instead of construct pGL3-C5-LUC.The results of these luciferase assays were further corroborated
by monitoring the levels of the AGC1 mRNA with real-time PCR
(Fig. 3B). Furthermore, to demonstrate the involvement of CREB,
in its active form, in the regulation AGC1 gene expression, we
compared the levels of phosphorylated CREB (P-CREB) protein
relative to total CREB (T-CREB) and AGC1 protein expression.
This analysis showed that AGC1 and P-CREB progressively and
simultaneously increased as a consequence of both CREB over-
expression and treatment with forskolin alone or in combination
(Fig. 3C and quantiﬁed in Fig. 3D). Signiﬁcantly, the addition of
H89 abolished any of these increasing effects (Fig. 3C). The analysis
of the relative ratio of P-CREB versus T-CREB with densitometry
further indicated that forskolin speciﬁcally induced the accumu-
lation of the active phosphorylated form of CREB. Speciﬁcally,
P-CREB increased progressively of 50, 100 and 150%, in presence of
pcDNA3-CREB, forskolin, and foskolin/pcDNA3-CREB, respectively,
relative to untreated cells (Fig. 3D). All of the above-reported
A. Menga et al. / The International Journal of Bioch
Fig. 2. Luciferase activity from AGC1 gene promoter constructs. Deletion analysis
of the 5′-ﬂanking region of the human AGC1 gene. The deletion fragments named
C1–C6 were cloned into the pGL3 basic-LUC vector and tested for LUC expression
activity in transfected SH-SY5Y cells. pGL3 indicates the pGL3 basic-LUC vector
alone. Numbering indicates the extent of fragments, while gray bars indicate LUC
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Octivity. The values were set relative to the pGL3. Means± S.D. of ﬁve duplicate
ndependent experiments are shown. The differences compared to the pGL3 were
nalyzed by one-way ANOVA. *P<0.05, ***P<0.001.
esults provide evidence for a direct involvement of active, phos-
horylated CREB in the regulation of AGC1 expression in SH-SY5Y
ells.
.3. The decrease in AGC1 expression in neuroinﬂammation is
ost likely caused by the downregulation of CREB
Having established that CREB is a main regulator of AGC1
xpression, we asked whether the decrease in AGC1 expression
ig. 3. Functional characterization of CREB.
A) SH-SY5Y transfectedwith pGL3-basic-Luc vector containing (C5) or not (C6) theCREBb
ith 10M forskolin for 3h, and addition of 10M H89 1h before forskolin were perfo
ndependent experiments.*P<0.05, **P<0.01, ***P<0.001 versus control (one-way ANOV
ransfected with pcDNA3-CREB and/or treated with 10M forskolin for 1h was used to q
efore forskolin. Data are expressed as means± S.D. of ﬁve duplicate independent experim
C) AGC1, P-CREB, T-CREB and -actin proteins of SH-SY5Y cells treated as above (B) wer
uantiﬁcation. A representative of four blots is shown. (D) Bands intensities of T-CREB and
ne software (Bio-Rad) and corrected for-actin. Data are expressed asmeans± S.D. of fouemistry & Cell Biology 60 (2015) 157–166 161
induced by the pro-inﬂammatory cytokines might be due to a
decrease in CREB expression. To this end, SH-SY5Y cells were
treated with TNF, IFN and IL-1 individually or in combination
for 24 and 96h; then cell lysates were prepared for immunoblot
analysis of the cellular P-CREB and T-CREB content. When SH-SY5Y
were exposed to individual cytokines for 24h no effect was found
on P-CREB and T-CREB (Fig. 4A), as conﬁrmed also by densitometric
analysis (Fig. 4B). A reduction of P-CREB and T-CREB protein (20%)
was evident only in the treatment with combination of cytokines
after 24h (Fig. 4A and B). Both P-CREB and T-CREB decreased sig-
niﬁcantly (40 and 30%, respectively), after 96h of treatment with
TNF and/or IFN alone. A dramatic decrease (70%) was observed
upon treatment with combination of cytokines, TNF+ IFN and
TNF+ IFN+ IL-1 (Fig. 4C and D). No effect was evident upon
IL-1 treatment. This reduction of CREB expression is fully consis-
tent with previous reports showing that chronic exposure to TNF,
IFN, IL-1, decreases CREB expression (Jambal et al., 2003). Fur-
thermore, A accumulation was shown to be inversely correlated
with CREB levels in the brain of patients with Alzheimer Disease
(Pugazhenthi et al., 2011). Other studies also reported that CREB-
mediated expression of brain-derived neurotrophic factor (BDNF),
B-cell lymphoma (Bcl-2) and baculovirus inhibitor of apoptosis
proteins repeat-containing proteins (BIRC) 3 and 4 is impaired in
neuroinﬂammation (Pugazhenthi et al., 2011). On this bases we
argue that the decrease in CREB content induced by TNF/IFN and
TNF/IFN/IL-1 could be likely linked to the reduction of AGC1
expression in neuroinﬂammation. However, at present other fac-
tors cannot be excluded to be involved in gene downregulation in
neuroinﬂammation.
inding site.Where indicated a cotransfectionwith pcDNA3-CREB and/or a treatment
rmed before luciferase assay. Data are expressed as means± S.D. of ﬁve duplicate
A). (B) Total RNA extracted from SH-SY5Y cells, which had been (where indicated)
uantify AGC1 mRNA by real-time PCR. Where indicated 10M H89 was added 1h
ents. *P<0.05, **P<0.01, ***P<0.001 versus untreated control (one-way ANOVA).
e immunodetected with speciﬁc antibodies. P-CREB blot was reprobed for T-CREB
P-CREB were analyzed densitometrically using a Fluor-S MultiImager and Quantity
r individual experiments. *P<0.05, **P<0.01, ***P<0.001 versus untreated control.
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Fig. 4. Downregulation of CREB in cytokine-treated SH-SY5Y cells. P-CREB, T-CREB and -actin proteins of SH-SY5Y cells treated or untreated with 500U/m IFN, 1000U/ml
TNF and 10ng/ml IL-1 individually or in cambination for 24h were immunodetected with speciﬁc antibodies. P-CREB blot was reprobed for T-CREB quantiﬁcation. Similar
results were obtained in four independent experiments. (B) The intensities of P-CREB and T-CREB in (A) were analyzed densitometrically using a Fluor-S MultiImager and
Quantity One software (Bio-Rad) and corrected for -actin. Data are expressed as means± S.D. of four individual experiments. *P<0.05, **P<0.01 versus untreated control
(one-way ANOVA). (C) P-CREB, T-CREB and -actin proteins of SH-SY5Y cells treated or untreated as above for 96h were immunodetected with speciﬁc antibodies. P-
CREB blot was reprobed for T-CREB quantiﬁcation. Similar results were obtained in four independent experiments. (D) The intensities of P-CREB and T-CREB in (C) were
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xperiments. *P<0.05, **P<0.01 versus untreated control.
.4. Cytosolic Ca2+ level affects AGC1 gene expression via CREB
Because Ca2+ is a well-known CREB inducer (Sheng and
reenberg, 1990) and is also known to stimulate AGC1 activity
Palmieri et al., 2001; Lasorsa et al., 2003; Contreras et al., 2007),
e investigated whether alterations in the pool of intracellular Ca2
ffect AGC1 gene expression. The inﬂuence of intracellular Ca2+
n AGC1 gene expression was studied by using two Ca2+ modu-
ators: BABTA-AM, a calcium chelator that penetrates live cells and
ecreases intracellular Ca2+ concentration (Petroni et al., 2013),
nd thapsigargin, which causes an increase in cellular Ca2+ level
y inhibiting the (sarco) endoplasmatic reticulum Ca2+-ATPase
SERCA) (Pulver et al., 2004). SH-SY5Y cells were transfected with
he pGL3-C5-LUC construct and incubated with 10M BABTA-AM
or 3h or 100nM thapsigargin for 6h. Because of its toxicity, it was
otpossible toprolong treatmentwithBAPTA-AMformore than3h
data not shown). BAPTA-AM decreased LUC activity by about 40%,
hereas thapsigargin increased it by about 80% (Fig. 5A). Notably,
hen the cells were transfected with the reporter luciferase con-
truct lacking the CREB binding site, the luciferase activity was
egligible (Fig. 5A), thus strongly arguing that Ca2+ acts via CREB.
he involvement of Ca2+ in the induction of AGC1 through CREB
as further demonstrated by using STO-609, a selective inhibitor
f Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK)
Tokumitsu et al., 2002). RT-PCR and Western blot showed that
oth AGC1 mRNA and protein levels were reduced by BAPTA-AM,
y CREB silencing and by STO-609, but they were increased by
hapsigargin and by combination of thapsigargin with pcDNA3-
REB (Fig. 5B and C). The pre-incubationwith STO-609 signiﬁcantlyad) and corrected for -actin. Data are expressed as means± S.D. of four individual
inhibited AGC1 mRNA and protein levels induced by thapsigar-
gin and thapsigargin/pcDNA3-CREB (Fig. 5B and C). Consistently,
P-CREB levels mirrored AGC1 expression. In fact, phosphorylated
CREB increased signiﬁcantlywhen intracellular Ca2+ was enhanced
(thapsigargin) and CREB was overexpressed in presence of thapsi-
gargin while it was reduced when Ca2+ was blocked by BAPTA-AM,
when Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK)
was inhibited by STO-609 and when CREB was silenced (Fig. 5C
and 5D). T-CREB increased only in presence of CREB overexpressing
plasmid. Of note, in presence of BAPTA, T-CREB content was unaf-
fected whereas P-CREB decreased suggesting the Ca2+ signaling
pathway in the activation of CREB. We next tested the effect of
siCREB on cell viability and growth was tested (Fig. S1). In another
set of experiments AGC1 gene expression was investigated in con-
ditions inwhich the levels of cellularN-acetylaspartate is increased
by treatment with neuregulin-1, a key regulator of the myelination
process (Birchmeier and Nave, 2008), which triggers an increase of
intracellular Ca2+mediated by phospholipase C-. When SH-SY5Y
cells were transfectedwith pGL3-C5-LUC construct in the presence
of neuregulin (20ng/ml) a signiﬁcant increase of LUC activity was
observed, whereas in the presence of BAPTA the activation was
abolished. Accordingly, neuregulin-1 also increased the amount of
AGC1 transcript and protein levels. As expected, BAPTA-AM abol-
ished this up-regulation, further suggesting the involvement of
Ca2+ in the induction of AGC1 expression (Fig. S2). Viewed together
these results provide the ﬁrst evidence that the levels of intracellu-
larCa2+ playakey role in regulationofAGC1genepromoter activity,
transcript and protein expression. Furthermore, the ﬁnding that
AGC1 is also induced by neuregulin is fully consistent with the
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Fig. 5. Effect of Ca2+ dysregulation onAGC1 expression. (A) SH-SY5Y cells transfectedwith pGL3-LUC constructs containing (C5) or not (C6) the CREB binding sitewere treated
with 100nM thapsigargin for 6h or 10M BAPTA-AM for 3h and then assayed for LUC expression activity. Data are expressed as means± S.D. of ﬁve duplicate independent
experiments. *P<0.05, versus control (one-way ANOVA). (B) AGC1 mRNA from SH-SY5Y cells exposed to the following treatment: 3h with 100nM thapsigargin or 10M
BAPTA-AM, transfection with pcDNA3-CREB and or with siCREB for 48h and treated with 100nM thapsigargin, preincubation with 10g/ml STO-609 for 1h followed by
addition of 100nM thapsigargin and, where indicated, by pcDNA3-CREB were quantiﬁed by real-time PCR. Data are expressed as means± S.D. of ﬁve duplicate independent
experiments. *P<0.05, **P<0.01 (one-way ANOVA). (C) AGC1, P-CREB, T-CREB and -actin proteins of SH-SY5Y cells treated as above. P-CREB blot was reprobed for T-CREB
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roposed role of this transporter inmyelination and further suggest
hat such activity is also dependent upon Ca2+.
Supplementary Figs. S1 and S2 related to this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.biocel.
015.01.004.
.5. CREB induces AGC1 gene expression during SH-SY5Y cell
ifferentiation
Since neurite outgrowth and differentiation require an increase
n energy production (Cheng et al., 2010) and AGC1 is one of
he most enriched proteins during neuronal cell differentiation
Watkins et al., 2008), we next asked whether AGC1 expression
hanges during differentiation of SH-SY5Y cells induced by the
BMX+db-cAMP combination (Deng et al., 2001) as inducer of
he CREB pathway. SH-SY5Y cell differentiation was induced with
00MIBMX+1mMdb-cAMP. Successful differentiationwas con-
rmed by the increase of neuronal markers SAP97 and SYP assayed
y immunoblot analysis (Fig. 6A). Real-time PCR performed on
RNA extracted from IBMX+db-cAMP-treated cells showed a sig-
iﬁcant increase of AGC1 mRNA level up to 3h of incubation
>100%) followed by a progressive decline until 72h (Fig. 6B).
onversely, immunoblot analysis performed on extracts derived
rom SH-SY5Y cells during differentiation showed an increase in
GC1 expression level after 6h, which remained elevated for 72h
Fig. 6C), suggesting a different mechanism of regulation for AGC1
ranscription and translation. P-CREB and T-CREB immunoblots
nd densitometric quantiﬁcation revealed that P-CREB increasedwn. (D) The intensities of P-CREBandT-CREB in (C)were analyzeddensitometrically
ctin. Data are expressed as means± S.D. of four individual experiments. *P<0.05,
and reached its maximum (>200%) for the ﬁrst 3h subsequently
followed by progressive decrease; whereas T-CREB content was
unchanged over the time (Fig. 6D and E). Of note, the levels of
P-CREB mirrored the AGC1 transcript proﬁle (Fig. 6B). To deter-
mine whether these changes were reﬂected in a time-dependent
differential recruitment of CREB on its DNA-binding consensus
sites during differentiation, we performed Electromobility Shift
Assays (EMSA) and Chromatin immunoprectipitation experiments
(ChIP). For the formers, cellular lysates derived from IBMX and db-
cAMP-treated SH-SY5Y cells were prepared at 1, 3, 6 and 24h and
incubated with a biotynilated probe containing the CREB binding
siteof theAGC1promoter. Inagreementwith the resultsof real time
PCR (Fig. 6B), the activation of CREB binding activitywasmaximally
stimulated within 3h after IBMX+db-cAMP treatment, (Fig. 6F). In
full agreementwith the results obtainedwithEMSA, theChIPassays
similarly demonstrated optimal CREB DNA binding activity on the
endogenous promoter following 3h of induction of differentiation.
After this time, a progressive reduction of CREB binding was evi-
dent for up to 72h, likely as a consequence of a reduction of P-CREB
level (Fig. 6G). In summary, our results show that CREB is actively
involved in AGC1 expression during SH-SY5Y cell differentiation.
4. DiscussionIn the present study, we have identiﬁed for the ﬁrst time
a regulatory element within the human AGC1 gene promoter
(comprised within 565–433bp) that contains a CRE site and whose
activity is exquisitely regulated by CREB during physiological and
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Fig. 6. Regulatory role of CREB during SH-SY5Y cell differentiation. (A) The two neuronal differentiation markers synaptophysin (SYP) and synapse-associated protein-97
(SAP97) and -actin of differentiated up to 72h or undifferentiated SH-SY5Y cells were immunodetected with speciﬁc antibodies. Similar results were obtained in three
independent experiments. (B) SH-SY5Y cellswere seeded onto 6-well plates and grown to 50% conﬂuence. The growthmediumwas replacedwith serum-freemedium for 16h
and the cellswere then stimulatedwith differentiationmedium consisting of serum-freemedium supplementedwith 0.5mM3-isobutyl-1-methylxanthine (IBMX) and 1mM
dibutyryl-cAMP (db-cAMP) for 1, 3, 6, 24 and 72h. Once the time of exposure was completed the cells were lysed and used to quantify AGC1 mRNA by real-time PCR. Data are
expressed as means± S.D. of ﬁve duplicate independent experiments. *P<0.05, **P<0.01 versus control (one-way ANOVA). (C) AGC1 and -actin proteins of differentiated
(up to 72h) or undifferentiated SH-SY5Y cells were immunodetected with speciﬁc antibodies. Similar results were obtained in three independent experiments. (D) P-CREB,
T-CREB and -actin proteins of differentiated (up to 72h) or undifferentiated SH-SY5Y cells were immunodetected with speciﬁc antibodies. P-CREB blot was reprobed for
T-CREB quantiﬁcation. Similar results were obtained in three independent experiments. (E) The intensities of P-CREB and T-CREB in (D) were analyzed densitometrically
using a Fluor-S MultiImager and Quantity One software (Bio-Rad) and corrected for -actin. Data are expressed as means± S.D. of four individual experiments. *P<0.05,
**P<0.01, versus untreated control. (F) The biotinylated probe from −531 to −511bp of AGC1 gene promoterwas incubated for 30minwith 10g of SH-SY5Y nuclear extracts
(SH-SY5Y NE) in the presence (lanes 3, 5, 7 and 9) or absence (lane 1) of 0.5mM IBMX and 1mM db-cAMP for the indicated time periods. Where indicated 10-fold excess
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athological signals. Among the reported results the following sup-
orting evidence can be mentioned. In neuronal SH-SY5Y cells
he overexpression of CREB enhances gene reporter expression
ctivity. Vice versa silencing of CREB reduces gene reporter activ-
ty. Consistently, the levels of both AGC1 transcript and protein
ere increased by overexpression of CREB and decreased by CREB
nock-down.
Our data also provide evidence that the CREB-induced activa-
ion of AGC1 gene transcription in SH-SY5Y cells is accomplished
y twoknownmechanisms leading tophosphorylationofCREB: the
AMP-dependent protein kinase pathway and the Ca2+ signaling to
REB pathway. The relevance of the cAMP-protein kinase pathway
n the regulation of AGC1 gene transcription is demonstrated by
he observation that forskolin, an activator of adenylate cyclase
Monaghan et al., 2008), increases, and H89, an inhibitor of the
AMP-dependent protein kinase pathway (Monaghan et al., 2008),
ecreases the luciferase reporter activity, AGC1 mRNA and AGC1
rotein levels. The role of Ca2+ signaling via the CREB pathway istiated (up to 72h) or undifferentiated SH-SY5Y cells was immunoprecipitated by
encompassing the AGC1 gene promoter from −565 to −409bp. Lanes No-Ab, PCR
further demonstrated by the inhibition of AGC1 gene expression
and protein levels by BAPTA-AM, which reduces intracellular Ca2+
(Petroni et al., 2013), as well as by its activation by thapsigargin,
which raises cytosolic Ca2+ (Pulver et al., 2004), and by inhibition of
Ca2+/calmodulin-dependent protein kinase-kinase [which inhibits
the phosphorylation of CaMKIV pathway (Tokumitsu et al., 2002)].
Furthermore, when CREB was silenced, changing intracellular Ca2+
had no effect on AGC1 mRNA and protein. Therefore, cytosolic Ca2+
regulates not only the activity of AGC1by reactingwith the EF-hand
Ca2+ binding sites present in the AGC1 N-terminal domain as pre-
viously shown (Palmieri et al., 2001; Lasorsa et al., 2003; Contreras
et al., 2007), but also activatesAGC1geneexpressionbyphosphory-
lating CREB. Interestingly, the higher levels of AGC1 transcript and
protein, together with higher Ca2+ levels, in post-mortem brains
from patients affected by autism as compared to control subjects
(Palmieri et al., 2010; Napolioni et al., 2011) can be hypothesized
to be due to a CREB-mediated increased AGC1 gene expression.
Furthermore, it is likely that excessive increase in AGC1 protein
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nd AGC1 activity as a consequence of sustained elevation of cel-
ular Ca2+ may affect global metabolism leading to oxidative stress
nd cellular dysfunction (Napolioni et al., 2011).
AGC1 plays an important role in the central nervous system
articularly in the process of myelination through the produc-
ion of NAA which is the precursor of myelin (Jalil et al., 2005;
adhavarao et al., 2005; Wibom et al., 2009). This involvement
s further showed in this study since SH-SY5Y cells treated with
euregulin, a key regulator of myelination process, which trigg-
rs an increase of intracellular Ca2+ mediated by phospholipase
, up-regulated AGC1 expression. In addition, CREB, which was
hown here to be a key positive transcriptional regulator of AGC1
ene expression, is known to activate transcription of target genes
nvolved in the growth, survival and synaptic plasticity of neu-
ons, memory, learning and mitochondrial biogenesis (Lonze and
inty, 2002). Most of CREB-dependent genes that encode enzymes
nvolved in energy production are down-regulated in neuroinﬂam-
ation and neurodegenerative disorders (Tong et al., 2001, 2004;
aura and Valero, 2011). For these reasons, in the present study the
egulation of AGC1 gene expression has been explored in neuronal
ells under pathological (inﬂammation) and physiological (differ-
ntiation) conditions.
Oxidative stress induced by cytokines is known to play
n important role in neurodegenerative process, such as in
lzheimer’s (Hensley et al., 1994; Nicolle et al., 2001). Since AGC1
s involved in energy production, in this work we evaluated the
ffect of cytokines, TNF, IFN and IL-1, on AGC1 expression.
mong the different treatments, a pronounced decrease of AGC1
RNA and protein in neuronal cells was observed upon treated
ith the combination of pro-inﬂammatory cytokines, TNF and
FN, and TNF, IFN and IL-1. Of note, the cytokines-mediated
own-regulation of AGC1 via CREB is exacerbated by prolonged
ro-inﬂammatory stimuli. Although the mechanism is not known,
t is very likely that oxidative stress, due to free radical genera-
ion and inﬂammatory responses, induces change in transcriptional
vents including down regulation of CREB and CREB-regulated
enes. It is noteworthy that in the oxidative stress CREB decreases
specially in the regions where astrocytes are abundant. Since
strocytes play an important role in neurodegeneration through
elease of cytokines (Wyss-Coray, 2006; Glass et al., 2010), it will
e interesting to evaluate the speciﬁc AGC1 expression in this
egion.
Neuronal differentiation is associatedwith increasedmitochon-
rial biogenesis and increased demand of metabolic energy (Cheng
t al., 2010). During neuronal cell differentiation we have found
CREB-dependent activation of AGC1 gene expression. In SH-
Y5Y cells the level of AGC1 protein was increased after 6h of
he CREB pathway induction with the IBMX+db-cAMP combina-
ion and remained elevated until 72h. The maximum increase in
GC1 transcript was reached after 3h of induction, as shown by
eal-time PCR, and parallels the increases of P-CREB, the binding of
he DNA CRE site to nuclear extracts and the anti-CREB antibody
mmunoprecipitated DNA. This ﬁnding suggests that the half-life
ime of AGC protein is markedly high.
In conclusion, we have demonstrated that CREB regulates AGC1
ene expression in neuronal cells via PKA/Ca2+-mediated activa-
ion. Since AGC1 is involved inmyelinogenesis, CREBmight be used
s drug target to increase AGC1 gene expression in neurodegener-
tive diseases.
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